Alpha 2.0
Login Register
» Articles » PMID: 9723329

Pirfenidone: a Novel Antifibrotic Agent with Implications for the Treatment of Obliterative Bronchiolitis

Overview
Journal Transplant Proc
Specialty General Surgery
Date 1998 Sep 2
PMID 9723329
Citations 4
Authors
A K Dosanjh
B Wan
W Throndset
S Sherwood
R E Morris
Affiliations
Soon will be listed here.
Citing Articles

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.

Mediavilla-Varela M, Boateng K, Noyes D, Antonia S BMC Cancer. 2016; 16:176.

PMID: 26935219 PMC: 4776434. DOI: 10.1186/s12885-016-2162-z.

Immunosuppression in lung transplantation.

Scheffert J, Raza K J Thorac Dis. 2014; 6(8):1039-53.

PMID: 25132971 PMC: 4133546. DOI: 10.3978/j.issn.2072-1439.2014.04.23.

In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion.

Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y PLoS One. 2011; 6(11):e28134.

PMID: 22132230 PMC: 3223242. DOI: 10.1371/journal.pone.0028134.

Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.

Visner G, Liu F, Bizargity P, Liu H, Liu K, Yang J Transplantation. 2009; 88(3):330-8.

PMID: 19667934 PMC: 2726969. DOI: 10.1097/TP.0b013e3181ae3392.